Clinical Trial Update: Exemestane Plus Everolimus for Hormone-receptor Positive Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 study evaluating exemestane plus everolimus for hormone receptor-positive metastatic breast cancer. The current status of the trial is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Afinitor (everolimus)
• Aromasin (exemestane)

Snippet

Sponsor: Organisation for Oncology and Translational Research | Conditions: Hormone Receptor Positive Malignant Neoplasm of Breast | Phase 2 | Status: UNKNOWN